Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CSCC

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Licensed to treat one of the most commonly diagnosed skin cancers

- PMLiVE

Scancell preps phase 2 challenge for melanoma vaccine

Progress continues for biotech

- PMLiVE

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Could add $1bn to revenues, say analysts

- PMLiVE

Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2

Success against placebo, but fails to outperform Dupixent

Sanofi reception

Sanofi sheds jobs in R&D restructuring

New R&D chief diverting funds to new therapy areas

- PMLiVE

Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

Move cuts pipeline depth, says GlobalData

- PMLiVE

Sanofi taps Google’s expertise for digital transformation

Pharma giant embraces AI with new partnership

- PMLiVE

Regeneron’s bispecific for lymphoma works in CAR-T failures

Regeneron has reported positive results with its REGN1979 drug in patients with non-Hodgkin’s lymphoma, including the evidence it can work in patients who have previously tried CAR-T therapies.The new data...

- PMLiVE

Hudson named Brandicourt’s successor as Sanofi’s CEO

Sanofi shaking off patent expiries

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Keytruda monotherapy fails in triple negative breast cancer

Fails in gambit to outflank rival Tecentriq

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links